VATE INNOVATE Corp.

NYSE innovatecorp.com


$ 4.58 $ 0.03 (0.67 %)    

Friday, 17-Oct-2025 15:59:53 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 4.53
$ 4.51
$ 4.04 x 1
$ 4.79 x 41
$ 4.44 - $ 4.68
$ 3.71 - $ 13.79
33,159
na
60.41M
$ 1.59
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 03-06-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 03-14-2023 12-31-2022 10-K
12 11-02-2022 09-30-2022 10-Q
13 08-03-2022 06-30-2022 10-Q
14 05-04-2022 03-31-2022 10-Q
15 03-09-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-06-2021 06-30-2021 10-Q
18 05-07-2021 03-31-2021 10-Q
19 03-10-2021 12-31-2020 10-K
20 11-09-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-11-2020 03-31-2020 10-Q
23 03-16-2020 12-31-2019 10-K
24 11-05-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-07-2019 03-31-2019 10-Q
27 03-12-2019 12-31-2018 10-K
28 11-06-2018 09-30-2018 10-Q
29 08-08-2018 06-30-2018 10-Q
30 05-10-2018 05-10-2018 10-Q
31 03-14-2018 12-31-2017 10-K
32 11-08-2017 09-30-2017 10-Q
33 08-09-2017 06-30-2017 10-Q
34 05-10-2017 03-31-2017 10-Q
35 03-09-2017 12-31-2016 10-K
36 11-09-2016 09-30-2016 10-Q
37 08-09-2016 06-30-2016 10-Q
38 05-09-2016 03-31-2016 10-Q
39 03-15-2016 12-31-2015 10-K
40 11-09-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 innovate-q2-eps-167-down-from-100-yoy-sales-24200m-down-from-31310m-yoy

Innovate (NYSE:VATE) reported quarterly losses of $(1.67) per share. This is a 267 percent decrease over earnings of $1.00 per ...

 reported-friday-innovate-announces-fda-approval-of-medibeacons-tgfr-system-for-accurate-kidney-function-testing

Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with norma...

 innovate-q3-eps-118-down-from-090-yoy-sales-24220m-down-from-37530m-yoy

Innovate (NYSE:VATE) reported quarterly losses of $(1.18) per share. This is a 31.11 percent decrease over losses of $(0.90) pe...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION